young-pearl: palbociclib plus exemestane and ofs in hr /her2- breast cancer
Published 3 months ago • 58 plays • Length 3:08Download video MP4
Download video MP3
Similar videos
-
3:30
final results from pallas: adjuvant palbociclib in hr /her2- early breast cancer
-
5:00
penelope-b: palbociclib with endocrine therapy in hr , her2-negative breast cancer
-
1:49
phase ib data capitello-292: capivasertib palbociclib fulvestrant in hr /her2- breast cancer
-
7:27
polaris: palbociclib for bipoc patients with her2-negative breast cancer
-
1:43
composite biomarkers predictive of palbociclib endocrine treatment benefit in early breast cancer
-
2:46
preliminary data on op-1250 palbociclib in advanced/metastatic er /her- breast cancer
-
2:02
palbociclib combined with fulvestrant in relapsed metastatic hr /her2- breast cancer
-
5:04
paloma-3: palbociclib and fulvestrant for hr-/her metastatic breast cancer
-
8:40
the pearl study: palbociclib and endocrine therapy vs capecitabine in hr /her2- metastatic breas...
-
6:29
study of palbociclib after cdk & endocrine therapy in er /her2- metastatic breast cancer
-
1:39
frontline endocrine therapies and ribociclib in early stage hr her2- breast cancer
-
1:29
capitello-292: capivasertib, palbociclib, and fulvestrant for hr endocrine-resistant breast cancer
-
1:45
real-world clinical outcomes in metastatic breast cancer patients treated with palbociclib
-
4:40
ameera-1 updates: amcenestrant plus palbociclib for patients with er /her2– advanced breast cancer
-
5:10
paloma-3: overall survival (os) with palbociclib plus fulvestrant in hr ,her2_ abc
-
2:56
parsifal-long: fulvestrant and palbociclib vs letrozole and palbociclib
-
8:25
paloma-1 study of palbociclib in er , her2-, breast cancer
-
2:29
breast cancer: palbociclib in later lines
-
2:21
palbociclib with adjuvant endocrine therapy in early breast cancer - pallas study